Correlation between BRCA1 expression and the advanced stage of triple‑negative breast cancer

Irianiwati,Irianiwati; Gurky,Thela Calcarina; Anwar,Sumadi Lukman; Bawono,Rheza Gandi; Dwianingsih,Ery Kus

doi:10.3892/mco.2025.2827

Correlation between BRCA1 expression and the advanced stage of triple‑negative breast cancer

Authors:
- Irianiwati Irianiwati
- Thela Calcarina Gurky
- Sumadi Lukman Anwar
- Rheza Gandi Bawono
- Ery Kus Dwianingsih
View Affiliations

Affiliations: Department of Anatomical Pathology, Faculty of Medicine, Public Health and Nursing, University Gadjah Mada/Sardjito General Hospital, Sekip, Yogyakarta 55281, Indonesia, Surgery Department, Faculty of Medicine, Public Health and Nursing, University Gadjah Mada/Sardjito General Hospital, Sekip, Yogyakarta 55281, Indonesia
Published online on: January 30, 2025 https://doi.org/10.3892/mco.2025.2827
Article Number: 32
Copyright: © Irianiwati et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Triple‑negative breast cancer (TNBC) is highly aggressive and has a poor prognosis. TNBC is commonly reported in young women and often relapses quickly, exhibiting aggressive characteristics. It is also linked to a loss of function of BRCA1. Patients with BRCA mutations require different treatments because this tumor type is sensitive to platinum‑based chemotherapy regimens and inhibitors of the poly (ADP ribose) polymerase. The present study aimed to investigate the prognostic significance of BRCA1 expression in Indonesian patients with TNBC. The study included 57 patients with TNBC. Epidermal growth factor receptor and cytokeratin 5/6 immunostaining were used to classify TNBC into basal‑like and non‑basal‑like subtypes. The BRCA1 expression was also determined using immunohistochemistry. Pearson's Chi‑square analysis and Fisher's exact test were used to examine correlations between variables. Kaplan‑Meier method was used to analyze the survival rate. Patients with TNBC had an average age of 55.18±10.014; most of them were ≥50 years‑old, had high‑grade tumors (75.4%), and were in the advanced stages of cancer (82.5%). The majority had no specific type of cancer (78.9%), received non‑platinum‑based therapies (64.9%), had basal‑like subtypes (72.9%), and were still alive (56.1%). Negative BRCA1 expression was higher (52.6%) than positive expression (47.4%) and correlated with advanced cancer stage (P=0.035). However, the BRCA1 expression was not correlated with other clinicopathological variables and the types of therapy. Survival analysis showed that the stage and BRCA1 expression acted as insignificant prognostic factors in patients with TNBC (P=0.091 and P=0.150). In the present study, negative BRCA1 expression was correlated with advanced stage but did not act as a prognostic factor in Indonesian patients with TNBC.

View Figures

View References

1	Boyle P: Triple-negative breast cancer: Epidemiological considerations and recommendations. Ann Oncol. 23 (Suppl 6):vi7–vi12. 2012.PubMed/NCBI View Article : Google Scholar
2	Yeh J, Chun J, Schwartz S, Wang A, Kern E, Guth AA, Axelrod D, Shapiro R and Schnabel F: Clinical characteristics in patients with triple negative breast cancer. Int J Breast Cancer. 2017(1796145)2017.PubMed/NCBI View Article : Google Scholar
3	Widodo I, Dwianingsih EK, Aryandono T and Soeripto S: Clinicopathological characteristic and prognostic significance of Indonesian triple-negative breast cancer. Indones Biomed J. 11:286–292. 2019.
4	Jang MH, Kim HJ, Kim EJ, Chung YR and Park SY: Expression of epithelial-mesenchymal transition-related markers in triple-negative breast cancer: ZEB1 as a potential biomarker for poor clinical outcome. Hum Pathol. 46:1267–1274. 2015.PubMed/NCBI View Article : Google Scholar
5	Fedele M, Cerchia L and Chiappetta G: The epithelial-to-mesenchymal transition in breast cancer: Focus on basal-like carcinomas. Cancers (Basel). 9(134)2017.PubMed/NCBI View Article : Google Scholar
6	Han J, Lim W, You D, Jeong Y, Kim S, Lee JE, Shin TH, Lee G and Park S: Chemoresistance in the human triple-negative breast cancer cell line MDA-MB-231 induced by doxorubicin gradient is associated with epigenetic alterations in histone deacetylase. J Oncol. 2019(1345026)2019.PubMed/NCBI View Article : Google Scholar
7	Bou Zerdan M, Ghorayeb T, Saliba F, Allam S, Bou Zerdan M, Yaghi M, Bilani N, Jaafar R and Nahleh Z: Triple negative breast cancer: Updates on classification and treatment in 2021. Cancers (Basel). 14(1253)2022.PubMed/NCBI View Article : Google Scholar
8	Yamamoto Y, Ibusuki M, Nakano M, Kawasoe T, Hiki R and Iwase H: Clinical significance of basal-like subtype in triple-negative breast cancer. Breast Cancer. 16:260–267. 2009.PubMed/NCBI View Article : Google Scholar
9	Toft DJ and Cryns VL: Minireview: Basal-like breast cancer: From molecular profiles to targeted therapies. Mol Endocrinol. 25:199–211. 2011.PubMed/NCBI View Article : Google Scholar
10	Badowska-Kozakiewicz AM and Budzik MP: Immunohistochemical characteristics of basal-like breast cancer. Contemp Oncol (Pozn). 20:436–443. 2016.PubMed/NCBI View Article : Google Scholar
11	Bao B, Mitrea C, Wijesinghe P, Marchetti L, Girsch E, Farr RL, Boerner JL, Mohammad R, Dyson G, Terlecky SR, et al: Treating triple negative breast cancer cells with erlotinib plus a select antioxidant overcomes drug resistance by targeting cancer cell heterogeneity. Sci Rep. 7(44125)2017.PubMed/NCBI View Article : Google Scholar
12	Jung J, Kang E, Gwak JM, Seo AN, Park SY, Lee AS, Baek H, Chae S, Kim EK and Kim SW: Association between basal-like phenotype and BRCA1/2 germline mutations in Korean breast cancer patients. Curr Oncol. 23:298–303. 2016.PubMed/NCBI View Article : Google Scholar
13	Maksimenko J, Irmejs A, Nakazawa-Miklasevica M, Melbarde-Gorkusa I, Trofimovics G, Gardovskis J and Miklasevics E: Prognostic role of BRCA1 mutation in patients with triple-negative breast cancer. Oncol Lett. 7:278–284. 2014.PubMed/NCBI View Article : Google Scholar
14	Botti G, Cantile M, Collina F, Cerrone M, Sarno S, Anniciello A and Di Bonito M: Morphological and pathological features of basal-like breast cancer. Transl Cancer Res. 8 (Suppl 5):S503–S509. 2019.PubMed/NCBI View Article : Google Scholar
15	Hussein IA, Ahmed ST, Hameedi AD, Naji RZ, Alharbawi L, Alkhaytt M and Pity IS: Immunohistochemical expression of BRCA1 protein, ER, PR and Her2/neu in breast cancer: A clinicopathological study. Asian Pac J Cancer Prev. 21:1025–1029. 2020.PubMed/NCBI View Article : Google Scholar
16	Abulkhair O, Moghraby JS, Badri M and Alkushi A: Clinicopathologic features and prognosis of triple-negative breast cancer in patients 40 years of age and younger in Saudi Arabia. Hematol Oncol Stem Cell Ther. 5:101–106. 2012.PubMed/NCBI View Article : Google Scholar
17	McGuire A, Brown JA, Malone C, McLaughlin R and Kerin MJ: Effects of age on the detection and management of breast cancer. Cancers (Basel). 7:908–929. 2015.PubMed/NCBI View Article : Google Scholar
18	Tzikas AK, Nemes S and Linderholm BK: A comparison between young and old patients with triple-negative breast cancer: Biology, survival and metastatic patterns. Breast Cancer Res Treat. 182:643–654. 2020.PubMed/NCBI View Article : Google Scholar
19	Badve S, Dabbs DJ, Schnitt SJ, Baehner FL, Decker T, Eusebi V, Fox SB, Ichihara S, Jacquemier J, Lakhani SR, et al: Basal-like and triple-negative breast cancers: A critical review with an emphasis on the implications for pathologists and oncologists. Mod Pathol. 24:157–167. 2011.PubMed/NCBI View Article : Google Scholar
20	Leidy J, Khan A and Kandil D: Basal-like breast cancer: Update on clinicopathologic, immunohistochemical, and molecular features. Arch Pathol Lab Med. 138:37–43. 2014.PubMed/NCBI View Article : Google Scholar
21	Guterson B and Eaves CJ: Basal-like breast cancers: From pathology to biology and back again. Stem Cell Reports. 10:1676–1686. 2018.PubMed/NCBI View Article : Google Scholar
22	Kim H, Cho DY, Choi DH, Choi SY, Shin I, Park W, Huh SJ, Han SH, Lee MH, Ahn SH, et al: Characteristics and spectrum of BRCA1 and BRCA2 mutations in 3,922 Korean patients with breast and ovarian cancer. Breast Cancer Res Treat. 134:1315–1326. 2012.PubMed/NCBI View Article : Google Scholar
23	Kwong A, Wong CHN, Suen DTK, Co M, Kurian AW, West DW and Ford JM: Accuracy of BRCA1/2 mutation prediction models for different ethnicities and genders: Experience in a southern Chinese cohort. World J Surg. 36:702–713. 2012.PubMed/NCBI View Article : Google Scholar
24	Sugano K, Nakamura S, Ando J, Takayama S, Kamata H, Sekiguchi I, Ubukata M, Kodama T, Arai M, Kasumi F, et al: Cross-sectional analysis of germline BRCA1 and BRCA2 mutations in Japanese patients suspected to have hereditary breast/ovarian cancer. Cancer Sci. 99:1967–1976. 2008.PubMed/NCBI View Article : Google Scholar
25	Hedau S, Batra M, Singh UR, Bharti AC, Ray A and Das BC: Expression of BRCA1 and BRCA2 proteins and their correlation with clinical staging in breast cancer. J Cancer Res Ther. 11:158–163. 2015.PubMed/NCBI View Article : Google Scholar
26	Shin S, Kim Y, Chul Oh S, Yu N, Lee ST, Rak Choi J and Lee KA: Validation and optimization of the Ion Torrent S5 XL sequencer and Oncomine workflow for BRCA1 and BRCA2 genetic testing. Oncotarget. 8:34858–34866. 2017.PubMed/NCBI View Article : Google Scholar
27	Mahmoud AM, Macias V, Al-Alem U, Deaton RJ, Kadjaksy-Balla A, Gann PH and Rauscher GH: BRCA1 protein expression and subcellular localization in primary breast cancer: Automated digital microscopy analysis of tissue microarrays. PLoS One. 12(e0184385)2017.PubMed/NCBI View Article : Google Scholar
28	Guney Eskiler G, Cecener G, Egeli U and Tunca B: Triple negative breast cancer: New therapeutic approaches and BRCA status. APMIS. 126:371–379. 2018.PubMed/NCBI View Article : Google Scholar
29	Costa REARD, Oliveira FTR, Araújo ALN and Vieira SC: Prognostic factors in triple-negative breast cancer: A retrospective cohort. Rev Assoc Med Bras (1992). 67:950–957. 2021.PubMed/NCBI View Article : Google Scholar
30	Chen B, Zhang X, Liu Y and Wang C: Prognostic disparities in young patients based on breast cancer subtype: A population-based study from the SEER database. Medicine (Baltimore). 102(e33416)2023.PubMed/NCBI View Article : Google Scholar